Login / Signup

Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper.

Ludger KlimekMarek JutelJean BousquetIoana AgacheMübeccel AkdisValerie HoxPhilippe GevaertPeter-Valentin TomazicCarmen RondónCemal CingiSanna Katriina Toppila-SalmiAspasia KaraveliaBanu BozkurtUlrike Förster-RuhrmannSven BeckerAdam M ChakerBarbara WollenbergRalph MosgesTilman HuppertzJan HagemannClaus BachertWytske Johanna Fokkens
Published in: Allergy (2021)
Intranasal corticosteroids remain the standard treatment for CRS in patients with SARS-CoV-2 infection. Surgical treatments should be reduced to a minimum and surgery preserved for patients with local complications and for those with no other treatment options. Systemic corticosteroids should be avoided. Treatment with biologics can be continued with careful monitoring in noninfected patients and should be temporarily interrupted during the course of the COVID-19 infection.
Keyphrases
  • end stage renal disease
  • minimally invasive
  • chronic kidney disease
  • newly diagnosed
  • ejection fraction
  • prognostic factors
  • risk factors
  • combination therapy
  • coronavirus disease
  • patient reported